NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-20-074 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.
Notice NOT-MH-20-011 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-20-069 from the NIH Guide for Grants and Contracts. The purpose of this award is to support phased transition of outstanding graduate students from groups underrepresented in the biomedical, clinical, behavioral and social sciences research enterprise from graduate work to postdoctoral research positions in Dental, Oral, and Craniofacial (DOC) research. The first phase (F99) will support the final two years of graduate research training for individuals in PhD or dual degree clinician scientist programs. Following graduation and attainment of a postdoctoral research position, the second phase (K00) will provide support for up to three years of mentored postdoctoral research.
Funding Opportunity PAR-20-072 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function system development and function; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases. Each P01 application submitted to this FOA must include at least two related research projects that share a common central theme, focus, and/or overall objective.
Funding Opportunity PAR-20-070 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.
Funding Opportunity PAR-20-071 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064, or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.
Funding Opportunity PAR-20-073 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is soliciting requests for access to dental practice-based research network (PBRN) resources for developmental/exploratory, pilot, and/or survey studies to be conducted in the to be conducted in the dental PBRN. Successful applicants will be given access to the NIDCR-funded dental PBRN infrastructure.
Funding Opportunity RFA-DK-19-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on Type 1 diabetes mellitus (T1D) that occurs after or as a consequence of one or more episodes of acute pancreatitis. Applications for the Clinical Centers (CC) are submitted in response to a separate FOA: RFA-DK-19-022: Type 1 Diabetes in Acute Pancreatitis Consortium Clinical Centers (T1DAPC-CC) (U01). The applicant for the Data Coordinating Center (DCC) must have experience serving as the DCC for studies on complex, clinical conditions, like the occurrence of diabetes mellitus (DM) after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and the DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes that occurs during an acute pancreatitis episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study will be designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes after acute pancreatitis.. The Consortia will also undertake studies on the identification of immune and genetic risk factors and biomarkers which predict the development of T1D in a racially, ethnically, and geographically diverse population of subjects who have recovered from one or more episodes of acute pancreatitis due to various identifiable etiologies. The DCC will provide overall project coordination, administration, quality control, data management and biostatistical support.
Funding Opportunity RFA-DK-19-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on diabetes mellitus, with an emphasis on Type 1 diabetes (T1D), that occurs after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes that occurs during an acute pancreatitis episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study will be designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes that occurs during or after one or more episodes of acute pancreatitis. The teams will also undertake studies on the identification of immune and genetic risk factors and biomarkers which predict the development of T1D in a racially, ethnically, and geographically diverse population of subjects who have impaired glucose tolerance or diabetes mellitus after one or more episodes of acute pancreatitis due to various identifiable etiologies. Applications for the Data Coordinating Center (DCC) are submitted in response to a separate FOA: RFA-DK-19-023: Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC) (U01).
Funding Opportunity RFA-AI-19-068 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Immune Tolerance Network. The major goal of this Network is to develop tolerogenic approaches for the treatment and prevention of disease in three clinical areas: asthma and allergic diseases; autoimmune diseases; and immune-mediated consequences of allotransplantation. The scope of research to be carried out includes: 1) the design and conduct of clinical trials at all phases to evaluate the safety and efficacy of investigational products and approaches for the induction and maintenance of immune tolerance in humans; 2) the design and conduct of mechanistic studies and the development of tolerance assays as integral components of the clinical trials undertaken, including establishing and directing a consortium of laboratories; and one or more biospecimen repositories, and 3) the provision of bioinformatics, data collection, validation and analysis resources. In addition, on a limited basis, the Network may support focused product development and nonclinical studies (e.g., toxicology, pharmacology, pharmacokinetics, etc.) essential for the subsequent evaluation of promising tolerance induction approaches in humans.
Notice NOT-OD-20-039 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-020 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-021 from the NIH Guide for Grants and Contracts
Notice NOT-PM-20-001 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-041 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AT-20-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that focus on developing resources by refining and testing key concepts that will advance and further support the study of emotional well-being in the field at large. This infrastructure support will facilitate research networks through meetings, conferences, small-scale pilot research, multidisciplinary cross training (such as intensive workshops, summer institutes, or visiting scholar programs), and information dissemination to foster the growth and development of research in the following priority areas: (1) Ontology and measurement of emotional well-being; (2) Mechanistic research on the role of emotional well-being in health; (3) Biomarkers of emotional well-being; (4) Prevention research (mechanisms-focused intervention development in target populations); (5) Technology and outcome measure development for mechanistic studies; (6) Development and validation of well-being measures.
Notice NOT-DA-20-024 from the NIH Guide for Grants and Contracts
Notice NOT-DA-20-016 from the NIH Guide for Grants and Contracts
Notice NOT-RM-20-005 from the NIH Guide for Grants and Contracts
Notice NOT-RM-20-004 from the NIH Guide for Grants and Contracts